FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296606610> ?p ?o ?g. }

• W2296606610 endingPage "3836" @default.
• W2296606610 startingPage "3836" @default.
• W2296606610 abstract "Abstract Abstract 3836 Background. In essential thrombocythemia (ET) patients history of thrombosis and age over 60 y are validated risk factors for thrombosis; the thrombocytosis is a constitutive abnormality associated with both thrombotic and hemorrhagic risk; JAK2 V617F mutation, leukocytosis, and male gender are candidate thrombotic risk factors. Aims. To evaluate in ET patients clinical-biological characteristics at diagnosis and their relationship with thrombosis occurrence before and after diagnosis. Methods. A cohort of ET patients of the Registro Italiano Trombocitemia (RIT) was retrospectively analysed. This preliminary report in detail considers data on thrombosis history. Results. A total of 977 patients, 387 males and 590 females, presented at diagnosis: median age 55 y, median PLT count 783 × 109/L, median WBC count 8.8 × 109/L, median Hb 14.1 g/dL, bone marrow fibrosis (grade >0) in 33% of cases, history of thrombosis in 189 cases (19.3%). The patients at high risk (age over 60 y and/or history of thrombosis) were 511 (52 %). The thrombosis history in univariate analysis was significantly related to: age over 60 y (p 0.001), male gender (p 0.045), low thrombocytosis (PLT <783 x109/L, p 0.001), leukocytosis (WBC >8.8 x109/L, p 0.01), and JAK2 V617F mutation (p 0.006). No relationship was found with the bone marrow fibrosis. The 977 patients, when both PLT count and WBC count at diagnosis were considered, were subdivided in four groups: group 1: 202 pts with low thrombocytosis and leukocytosis; group 2: 270 pts with low thrombocytosis and no leukocytosis; group 3: 272 pts with high thrombocytosis and leukocytosis; group 4: 197 pts with high thrombocytosis and no leukocytosis. In those patients, the thrombosis history was: 26.7% in the group 1(both risk factors); 24.1% in the group 2 (PLT risk factor); 20.2% in the group 3 (WBC risk factor); 7.6% in the group 4 (no risk factors). The rate of thrombosis history in patients with one or two of these risk factors was significantly (p 0.001) higher than in patients with no risk factors. The thrombotic events during the follow up (4088 pt-y) are still object of analysis. Conclusion. In this cohort of ET patients the rate of thrombosis history in univariate analysis was related to age over 60 y. Moreover, a significant relationship was found with PLT count at diagnosis below the median value (783 x109/L), WBC count at diagnosis over the median value (8.8 x109/L), JAK2 V617F mutation, and male gender. Disclosures: No relevant conflicts of interest to declare." @default.
• W2296606610 created "2016-06-24" @default.
• W2296606610 creator A5003619706 @default.
• W2296606610 creator A5006810419 @default.
• W2296606610 creator A5008566093 @default.
• W2296606610 creator A5009340562 @default.
• W2296606610 creator A5009381933 @default.
• W2296606610 creator A5013237232 @default.
• W2296606610 creator A5018412128 @default.
• W2296606610 creator A5019087367 @default.
• W2296606610 creator A5019630321 @default.
• W2296606610 creator A5019993467 @default.
• W2296606610 creator A5023661824 @default.
• W2296606610 creator A5024214894 @default.
• W2296606610 creator A5024587881 @default.
• W2296606610 creator A5024650466 @default.
• W2296606610 creator A5027094790 @default.
• W2296606610 creator A5027976002 @default.
• W2296606610 creator A5033613825 @default.
• W2296606610 creator A5035566807 @default.
• W2296606610 creator A5037391469 @default.
• W2296606610 creator A5039359872 @default.
• W2296606610 creator A5041745367 @default.
• W2296606610 creator A5045651843 @default.
• W2296606610 creator A5046772202 @default.
• W2296606610 creator A5047421266 @default.
• W2296606610 creator A5053851132 @default.
• W2296606610 creator A5056630421 @default.
• W2296606610 creator A5057593886 @default.
• W2296606610 creator A5059776581 @default.
• W2296606610 creator A5061602224 @default.
• W2296606610 creator A5066768069 @default.
• W2296606610 creator A5071466957 @default.
• W2296606610 creator A5072484806 @default.
• W2296606610 creator A5076571467 @default.
• W2296606610 creator A5078392742 @default.
• W2296606610 date "2011-11-18" @default.
• W2296606610 modified "2023-09-26" @default.
• W2296606610 title "Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT)," @default.
• W2296606610 doi "https://doi.org/10.1182/blood.v118.21.3836.3836" @default.
• W2296606610 hasPublicationYear "2011" @default.
• W2296606610 type Work @default.
• W2296606610 sameAs 2296606610 @default.
• W2296606610 citedByCount "1" @default.
• W2296606610 countsByYear W22966066102021 @default.
• W2296606610 crossrefType "journal-article" @default.
• W2296606610 hasAuthorship W2296606610A5003619706 @default.
• W2296606610 hasAuthorship W2296606610A5006810419 @default.
• W2296606610 hasAuthorship W2296606610A5008566093 @default.
• W2296606610 hasAuthorship W2296606610A5009340562 @default.
• W2296606610 hasAuthorship W2296606610A5009381933 @default.
• W2296606610 hasAuthorship W2296606610A5013237232 @default.
• W2296606610 hasAuthorship W2296606610A5018412128 @default.
• W2296606610 hasAuthorship W2296606610A5019087367 @default.
• W2296606610 hasAuthorship W2296606610A5019630321 @default.
• W2296606610 hasAuthorship W2296606610A5019993467 @default.
• W2296606610 hasAuthorship W2296606610A5023661824 @default.
• W2296606610 hasAuthorship W2296606610A5024214894 @default.
• W2296606610 hasAuthorship W2296606610A5024587881 @default.
• W2296606610 hasAuthorship W2296606610A5024650466 @default.
• W2296606610 hasAuthorship W2296606610A5027094790 @default.
• W2296606610 hasAuthorship W2296606610A5027976002 @default.
• W2296606610 hasAuthorship W2296606610A5033613825 @default.
• W2296606610 hasAuthorship W2296606610A5035566807 @default.
• W2296606610 hasAuthorship W2296606610A5037391469 @default.
• W2296606610 hasAuthorship W2296606610A5039359872 @default.
• W2296606610 hasAuthorship W2296606610A5041745367 @default.
• W2296606610 hasAuthorship W2296606610A5045651843 @default.
• W2296606610 hasAuthorship W2296606610A5046772202 @default.
• W2296606610 hasAuthorship W2296606610A5047421266 @default.
• W2296606610 hasAuthorship W2296606610A5053851132 @default.
• W2296606610 hasAuthorship W2296606610A5056630421 @default.
• W2296606610 hasAuthorship W2296606610A5057593886 @default.
• W2296606610 hasAuthorship W2296606610A5059776581 @default.
• W2296606610 hasAuthorship W2296606610A5061602224 @default.
• W2296606610 hasAuthorship W2296606610A5066768069 @default.
• W2296606610 hasAuthorship W2296606610A5071466957 @default.
• W2296606610 hasAuthorship W2296606610A5072484806 @default.
• W2296606610 hasAuthorship W2296606610A5076571467 @default.
• W2296606610 hasAuthorship W2296606610A5078392742 @default.
• W2296606610 hasConcept C126322002 @default.
• W2296606610 hasConcept C141071460 @default.
• W2296606610 hasConcept C144301174 @default.
• W2296606610 hasConcept C2778923028 @default.
• W2296606610 hasConcept C2779788118 @default.
• W2296606610 hasConcept C2780868729 @default.
• W2296606610 hasConcept C2781057849 @default.
• W2296606610 hasConcept C38180746 @default.
• W2296606610 hasConcept C71924100 @default.
• W2296606610 hasConcept C72563966 @default.
• W2296606610 hasConcept C89560881 @default.
• W2296606610 hasConcept C90924648 @default.
• W2296606610 hasConceptScore W2296606610C126322002 @default.
• W2296606610 hasConceptScore W2296606610C141071460 @default.
• W2296606610 hasConceptScore W2296606610C144301174 @default.
• W2296606610 hasConceptScore W2296606610C2778923028 @default.
• W2296606610 hasConceptScore W2296606610C2779788118 @default.
• W2296606610 hasConceptScore W2296606610C2780868729 @default.

• next